secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVITA Medical, Inc. (RCEL)
CIK:        0001762303
Form:       8-K
Filed at:   2023-10-18T23:59:59+00:00
Accession:  0000950170-23-053882
Event type: debt
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.02, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVITA Medical secures $90M debt facility from OrbiMed; prelim Q3 revenue $13.5M (+50% YoY)
--------------------------------------------------------------------------------

- Preliminary Q3 commercial revenue $13.5M, +50% YoY from ~$9.0M; gross margin ~84.5%.
- Full-year 2023 revenue guidance unchanged at $51-53M.
- $40M funded at close; up to $50M more available in two tranches based on revenue thresholds.
- Five-year term matures Oct 2028; OrbiMed gets warrant for 409,661 shares at $10.9847.
- Management expects financing to fund growth and support reaching profitability during 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1762303/000095017023053882/0000950170-23-053882-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1762303/000095017023053882/rcel-20231018.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-053882

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer